Gilead Sciences has entered into a licence agreement with Tibotec Pharmaceuticals to develop and market a single-tablet regimen comprising Prezista (darunavir), Emtriva (emtricitabine, GS7340) and cobicistat, a pharmacoenhancer.

Under the agreement, Gilead will be responsible for the formulation, manufacturing, registration, distribution and commercialisation of the single-tablet regimen worldwide, while Tibotec will co-detail the single-tablet regimen in certain major markets.

Gilead Sciences chief scientific officer Norbert Bischofberger said that his is the first time the company is developing a protease inhibitor-containing single-tablet regimen, due to the small milligram size of GS 7340.

"We are pleased to once again be partnering with Tibotec to advance and simplify HIV treatment for patients," Bischofberger added.

Gilead plans to begin a Phase II study of GS 7340, an anti-HIV agent, in 2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.